218 related articles for article (PubMed ID: 32468494)
1. Behavioral and Molecular Basis of Cholinergic Modulation of Pain: Focus on Nicotinic Acetylcholine Receptors.
Toma W; Ulker E; Alqasem M; AlSharari SD; McIntosh JM; Damaj MI
Curr Top Behav Neurosci; 2020; 45():153-166. PubMed ID: 32468494
[TBL] [Abstract][Full Text] [Related]
2. Allosteric modulation of α4β2* nicotinic acetylcholine receptors: Desformylflustrabromine potentiates antiallodynic response of nicotine in a mouse model of neuropathic pain.
Bagdas D; Ergun D; Jackson A; Toma W; Schulte MK; Damaj MI
Eur J Pain; 2018 Jan; 22(1):84-93. PubMed ID: 28809075
[TBL] [Abstract][Full Text] [Related]
3. α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain.
Nirogi R; Goura V; Abraham R; Jayarajan P
Eur J Pharmacol; 2013 Jul; 712(1-3):22-9. PubMed ID: 23660369
[TBL] [Abstract][Full Text] [Related]
4. Modeling subtype-selective agonists binding with alpha4beta2 and alpha7 nicotinic acetylcholine receptors: effects of local binding and long-range electrostatic interactions.
Huang X; Zheng F; Chen X; Crooks PA; Dwoskin LP; Zhan CG
J Med Chem; 2006 Dec; 49(26):7661-74. PubMed ID: 17181149
[TBL] [Abstract][Full Text] [Related]
5. Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies.
Pandya AA; Yakel JL
Biochem Pharmacol; 2013 Oct; 86(8):1054-62. PubMed ID: 23732296
[TBL] [Abstract][Full Text] [Related]
6. Small molecule ligands for α9 * and α7 nicotinic receptors: A survey and an update, respectively.
Giraudo A; Pallavicini M; Bolchi C
Pharmacol Res; 2023 Jul; 193():106801. PubMed ID: 37236412
[TBL] [Abstract][Full Text] [Related]
7. Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.
Grupe M; Grunnet M; Bastlund JF; Jensen AA
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):187-200. PubMed ID: 25441336
[TBL] [Abstract][Full Text] [Related]
8. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A
J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536
[TBL] [Abstract][Full Text] [Related]
9. Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor.
Faghih R; Gfesser GA; Gopalakrishnan M
Recent Pat CNS Drug Discov; 2007 Jun; 2(2):99-106. PubMed ID: 18221220
[TBL] [Abstract][Full Text] [Related]
10. Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling.
Parikh V; Ji J; Decker MW; Sarter M
J Neurosci; 2010 Mar; 30(9):3518-30. PubMed ID: 20203212
[TBL] [Abstract][Full Text] [Related]
11. Differential involvement of α4β2, α7 and α9α10 nicotinic acetylcholine receptors in B lymphocyte activation in vitro.
Koval L; Lykhmus O; Zhmak M; Khruschov A; Tsetlin V; Magrini E; Viola A; Chernyavsky A; Qian J; Grando S; Komisarenko S; Skok M
Int J Biochem Cell Biol; 2011 Apr; 43(4):516-24. PubMed ID: 21146628
[TBL] [Abstract][Full Text] [Related]
12. Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators.
Wilkerson JL; Deba F; Crowley ML; Hamouda AK; McMahon LR
Neuropharmacology; 2020 May; 168():108008. PubMed ID: 32113032
[TBL] [Abstract][Full Text] [Related]
13. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them.
Xiao Y; Fan H; Musachio JL; Wei ZL; Chellappan SK; Kozikowski AP; Kellar KJ
Mol Pharmacol; 2006 Oct; 70(4):1454-60. PubMed ID: 16857741
[TBL] [Abstract][Full Text] [Related]
14. A silent agonist of α7 nicotinic acetylcholine receptors modulates inflammation ex vivo and attenuates EAE.
Godin JR; Roy P; Quadri M; Bagdas D; Toma W; Narendrula-Kotha R; Kishta OA; Damaj MI; Horenstein NA; Papke RL; Simard AR
Brain Behav Immun; 2020 Jul; 87():286-300. PubMed ID: 31874200
[TBL] [Abstract][Full Text] [Related]
15. Nicotinic acetylcholine receptors: Therapeutic targets for novel ligands to treat pain and inflammation.
Hone AJ; McIntosh JM
Pharmacol Res; 2023 Apr; 190():106715. PubMed ID: 36868367
[TBL] [Abstract][Full Text] [Related]
16. Review: The nicotinic modulation of pain.
Bektas N; Nemutlu D; Cam M; Okcay Y; Eken H; Arslan R
Pak J Pharm Sci; 2020 Jan; 33(1):229-239. PubMed ID: 32122853
[TBL] [Abstract][Full Text] [Related]
17. DM506 (3-Methyl-1,2,3,4,5,6-hexahydroazepino[4,5-
Tae HS; Ortells MO; Tekarli BJ; Manetti D; Romanelli MN; McIntosh JM; Adams DJ; Arias HR
ACS Chem Neurosci; 2023 Jul; 14(14):2537-2547. PubMed ID: 37386821
[TBL] [Abstract][Full Text] [Related]
18. New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs.
Bagdas D; Gurun MS; Flood P; Papke RL; Damaj MI
Curr Neuropharmacol; 2018; 16(4):415-425. PubMed ID: 28820052
[TBL] [Abstract][Full Text] [Related]
19. New quinoline derivatives as nicotinic receptor modulators.
Manetti D; Bellucci C; Dei S; Teodori E; Varani K; Spirova E; Kudryavtsev D; Shelukhina I; Tsetlin V; Romanelli MN
Eur J Med Chem; 2016 Mar; 110():246-58. PubMed ID: 26840365
[TBL] [Abstract][Full Text] [Related]
20. Modulators of nicotinic acetylcholine receptors as analgesics.
Jain KK
Curr Opin Investig Drugs; 2004 Jan; 5(1):76-81. PubMed ID: 14983978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
